Though, tabalumab's Phase II clinical studies showed success and proved effective, a recent report has revealed that Eli Lilly and Company's human monoclonal antibody failed in terms of meeting efficacy objectives in a next-stage trial.

Of total three Phase 3 rheumatoid arthritis registration studies, one study of the anti-BAFF monoclonal antibody failed, which the researchers say, was totally unexpected. However, the failure is in no way related to safety concerns.

Therefore, as per the findings, patients currently involved in other studies of tabalumab RA would continue the treatment. Lilly would also be working towards the development of additional treatment options so that patients with autoimmune diseases could have an option.

It has been told that the company would evaluate the candidate in two other studies related to Phase 3 RA registration following the open-label extension study as well as other smaller studies. Since, the company is of the belief that it does not have sufficient data to gain U. S. marketing clearance.

"We remain committed to patients with rheumatoid arthritis and lupus and will move rapidly to evaluate the impact of these data on the overall tabalumab clinical development programme", sources quoted vice president for Lilly autoimmune product development Eiry Roberts as saying.